DBV Technologies (DBVT) announced that it will present additional data from the positive VITESSE Phase 3 study of the VIASKIN Peanut Patch in children ages 4-7 years at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting, in Philadelphia, taking place on February 27- March 2, 2026.
The company plans to submit a BLA to the U.S. FDA in the first half of 2026. The VIASKIN Peanut Patch has already received Breakthrough Therapy Designation, and DBV expects the filing may be eligible for priority review.
The company ended September 30, 2025, with cash of $69.8 million, providing runway into the third quarter of 2026.
The stock has traded between $3.82 to $26.18 over the past year. DBVT closed yesterday's trading at $23.80, up 7.11%, and fell in the pre-market to $22.76, down 4.37%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.